The Modified Selenenyl Amide, M-hydroxy Ebselen, Attenuates Diabetic Nephropathy and Diabetes-Associated Atherosclerosis in ApoE/GPx1 Double Knockout Mice

Sih Min Tan¹, Arpeeta Sharma¹, Derek Y. C. Yuen¹, Nada Stefanovic¹, Guy Krippner², Govindasamy Mugesh³, Zhonglin Chai⁴, Judy B. de Haan¹*

¹Oxidative Stress Group, Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia, ²Medicinal Chemistry, Baker IDI Heart and Diabetes Institute, Melbourne, Australia, ³Department of Inorganic & Physical Chemistry, Indian Institute of Science, Bangalore, India, ⁴Proliferation and Fibrosis Group, Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia

Abstract

Seleno-organic glutathione peroxidase (GPx) mimetics, including ebselen (Eb), have been tested in in vitro studies for their ability to scavenge reactive oxygen and nitrogen species, including hydrogen peroxide and peroxynitrite. In this study, we investigated the efficacies of two Eb analogues, M-hydroxy ebselen (ME) and ethanol-ebselen (EtE) and compared these with Eb in cell based assays. We found that ME is superior in attenuating the activation of hydrogen peroxide-induced pro-inflammatory mediators, ERK and P38 in human aortic endothelial cells. Consequently, we investigated the effects of ME in an in vivo model of diabetes, the ApoE/GPx1 double knockout (dKO) mouse. We found that ME attenuates plaque formation in the aorta and lesion deposition within the aortic sinus of diabetic dKO mice. Oxidative stress as assessed by 8-OHdG in urine and nitrotyrosine immunostaining in the aortic sinus and kidney tubules, was reduced by ME in diabetic dKO mice. ME also attenuated diabetes-associated renal injury which included tubulointerstitial fibrosis and glomerulosclerosis. Furthermore, the bioactivity of the pro-fibrotic cytokine transforming growth factor-β (TGF-β) as assessed by phospho-Smad2/3 immunostaining was attenuated after treatment with ME. TGF-β-stimulated increases in collagen I and IV gene expression and protein levels were attenuated by ME in rat kidney tubular cells. However, in contrast to the superior activity of ME in in vivo and cell based assays, ME did not further augment the attenuation of diabetes-associated atherosclerosis and renal injury in our in vivo model when compared with Eb. In conclusion, this study strengthens the notion that bolstering GPx-like activity using synthetic mimetics may be a useful therapeutic strategy in lessening the burden of diabetic complications. However, these studies highlight the importance of in vivo analyses to test the efficacies of novel Eb analogues, as in vitro and cell based assays are only partly predictive of the in vivo situation.

Introduction

Oxidative stress is recognised as playing a major role in the pathophysiology of disease, with evidence for its contribution to processes such as inflammation, fibrosis, and atherosclerotic lesion formation [1]. The two-electron reactive oxygen and nitrogen species (RO/NS) such as hydrogen peroxide and peroxynitrite (PN, ONOO⁻) are now considered more damaging than one-electron radicals, with greater disease-mediating capabilities [2]. Peroxynitrite is formed in biological reactions through the diffusion-controlled interaction of superoxide radicals (O₂⁻) with nitric oxide (NO) and is involved in DNA [3] and lipid damage [4] as well as the nitrosative damage of proteins via the formation of nitrotyrosine adducts [3,6]. Hydrogen peroxide mediates adverse cellular consequences at supraphysiological concentrations by enhancing processes such as apoptosis and necrosis [7,8], and affecting important pro-atherogenic pathways such as the JNK and MAP-kinase pathways [9,10,11]. Given the injurious nature of these two-electron reactive species, attention has focused on antioxidants to lower the concentration of these RO/NS to avert disease. Recent interest has turned to the benefits of bolstering endogenous antioxidant-like defences, in particular that of the naturally occurring glutathione peroxidase (GPx) enzymes, since these antioxidants efficiently remove two-electron reactive species such as hydrogen and lipid peroxides as well as peroxynitrites [12]. The development of small synthetic compounds that mimic the activities of the GPx enzymes have received considerable attention for their potential to lessen prevailing RO/NS and thereby reverse or avert disease [13,14].

Diabetes mellitus is one such disease where RO/NS cause cellular injury, in particular oxidative and nitrosative damage...
associated with its complications of atherosclerosis and kidney injury [15,16]. Renal and vascular dysfunction share several common underlying pathogenic mechanisms, with oxidative stress and systemic inflammation contributing to both diabetic pathologies [17,18,19]. Indeed, the effective targeting of oxidative stress in diabetic patients could lead to a reduction in atherosclerosis and kidney damage. Furthermore, diabetic patients often display atherosclerosis and kidney failure as co-morbidities, highlighting the potential of a targeted antioxidant mono-therapy effective against both conditions.

Recently, we have shown in *in vitro* studies that the lipid-soluble low molecular weight seleno-organic GPx mimetic, ebselen (Eb), as well as a range of Eb analogues, act as efficient catalysts in the decomposition of peroxynitrite [20]. Our studies were in agreement with previous investigations showing the interaction of Eb with PN to be 3–4 orders greater than that observed with other antioxidants such as cysteine, ascorbate or methione [21].

![Proposed catalytic mechanism of ebselen and the structure of ebselen and novel analogues. A) GPx cycle of ebselen: In a first step, selenium within the active site of ebselen (A) interacts with one glutathione molecule to form the selenenyl sulphide, ebselen-S-GSH (B). Interaction with another GSH produces the active ebselen-selenol (C), which then interacts with biological peroxides to produce ebselen-selenenic acid (D). This moiety in turn can either interact with GSH to regenerate ebselen-S-GSH (B) or via the formation of water, the selenenyl amide, ebselen (A) is regenerated. GSH, reduced glutathione; GSSG, oxidised glutathione dimer; ROOH represents biological peroxides. B) Structures of ebselen (Eb), ethanol-ebselen (EtE) and m-hydroxy ebselen (ME).](image-url)
Importantly, our study suggested that the efficacy of Eb could be further enhanced by suitable substitutions at its phenyl ring. Indeed we showed that the addition of a hydroxyl group in the meta- or 3- position of the phenyl ring of Eb (m-hydroxy ebselen or ME) reduced the IC₅₀ for the inhibition of PN-mediated nitration of L-tyrosine by approximately 2.5 fold compared with Eb, suggesting that the modified analogue ME behaves in a superior fashion to Eb in our in vitro assays [20]. Indeed, we have previously shown that any substituent that enhances the nucleophilic attack of a thiol at the sulfur centre in the selenenyl sulfide state (B, Figure 1A), enhances the antioxidant potency of the compound by reducing the barrier for the formation of the active species selenol (C, Figure 1A) [22].

However, it becomes important to test these compounds in cellular models since selenium compounds showing good catalytic activity in in vitro experiments cannot be assumed to show good antioxidant behavior in vivo. For this reason, we have now compared the efficacy of two modified Eb analogues [ME and ethanol-ebselen (EtE), an analogue with an ethanol substitution on the nitrogen atom of the 5-membered ring of Eb; see Figure 1B] with Eb in cell based assays. Based on our previous in vitro studies [20,23] and our current cell culture studies, we chose one analogue for further testing in animal models of diabetes. Consequently, we have now compared the efficacy of ME with Eb in the reduction of oxidative stress, atherogenic lesions and the ability to lessen endpoints of kidney disease in our well established diabetic model, the diabetic ApoE/GPx1 double knockout (dKO) mouse. Our rationale for these in vivo experiments was two-fold; firstly to establish whether ME lessened oxidative stress and limited the development of diabetic complications in the diabetic ApoE/GPx1 dKO mouse [24], and secondly to confirm our in vitro data that this modification of Eb rendered the behavior of ME superior to that of Eb [25] in vivo. Our results have shown that the modified Eb analogue, ME, attenuates oxidative stress, atherosclerosis and the hallmarks of diabetic nephropathy in the diabetic ApoE/GPx1 dKO mouse. However, our results highlight that the superior in vitro activity of this modified Eb analogue does not guarantee its superior in vivo function when compared with the parent compound Eb.

**Figure 2.** ERK and P38 phosphorylation in HAECs treated with hydrogen peroxide and ebselen or its analogues. A) 200 μM hydrogen peroxide (H₂O₂) treatment of human aortic endothelial cells (HAEC) results in a ~2-fold increase in ERK phosphorylation and a ~10-fold increase in P38 phosphorylation. Treatment with ebselen at 0.01 μM does not affect the H₂O₂–induced phosphorylation of either ERK or P38. **P<0.001 vs control (con), DMSO and ebselen (Eb) treated cells.*** B) Treatment of HAEC with m-hydroxy ebselen (ME) or ethanol ebselen (EtE) results in a ~75% and 50% reduction in ERK phosphorylation (pERK), respectively. In this experiment, basal levels for pERK were elevated in control cells most likely as a result of the later passage of these cells. **P<0.01** and ***P<0.001 vs H₂O₂ treated cells. C) 200 μM H₂O₂ treatment of HAEC results in a ~15-fold increase in P38 phosphorylation. Treatment with ME or EtE at 0.01 μM significantly reduced the H₂O₂-induced phosphorylation of P38. ***P<0.001 vs control (con), **P<0.01 vs H₂O₂ treated cells.

doi:10.1371/journal.pone.0069193.g002
with 0.01 M hydrogen peroxide (H$_2$O$_2$; 200 μM, Merck) was added for an additional 30 min in the presence of Eb or the analogues. In separate experiments, control cells were either not treated or treated with 200 μM H$_2$O$_2$ for 30 min; DMSO (vehicle control) or 0.01 μM drug alone for 60 min. In previously published studies, we had determined that treatment with 0.01–0.03 μM Eb was optimal for the inhibition of JNK and IKK activation, whilst significantly inhibiting Nox2 and TNF-α, and without compromising cell viability [26].

Table 1. Basic characteristics (clinical parameters).

|                     | ND (n = 9) | NDxME (n = 6) | Diab (n = 5) | DiabxEb (n = 8) | DiabxME (n = 6) |
|---------------------|------------|---------------|--------------|-----------------|-----------------|
| BW, g               | 28.8±0.5   | 27.7±0.7      | 24.2±0.9**   | 23.1±1.1***     | 23.0±0.8**      |
| HbA1c, %            | 5.2±0.2    | 4.7±0.2       | 17.0±1.0***  | NA              | 18.0±0.6***     |
| Blood glucose, mmol/L | 12.2±1.0  | 8.3±1.0       | 28.6±2.9***  | 24.2±2.0***     | 26.6±1.9***     |
| Total cholesterol, mmol/L | 5.8±0.5  | 5.5±0.4       | 10.4±2.2     | 8.2±1.2         | 7.1±0.7         |
| Triglycerides, mmol/L | 1.9±0.5   | 2.0±0.2       | 3.5±0.8      | 3.4±0.5         | 3.2±0.4         |
| HDL, mmol/L         | 1.2±0.1    | 1.2±0.1       | 2.2±0.5      | 1.7±0.3         | 1.3±0.2         |
| LDL, mmol/L         | 3.7±0.3    | 3.4±0.3       | 6.6±1.5      | 5.0±0.8         | 4.3±0.5         |
| R.Kid weight:BW, mg/g | 7.0±0.2   | 6.5±0.1       | 10.2±0.5***  | 10.0±0.5***     | 10.5±0.2***     |
| L.Kid weight:BW, mg/g | 7.1±0.3   | 6.6±0.2       | 10.1±0.6***  | 9.8±0.4***      | 10.2±0.3***     |
| UACR, mg/mmol       | 20.9±3.3   | 18.1±2.8      | 65.0±11.6**  | 512±9.3*        | 39.9±12.1       |

*p<0.05; **p<0.01; ***p<0.001 vs non-diabetic ApoE/GPx1 dKO mice.

ND, non-diabetic; Diab, diabetic; ME, m-hydroxy ebselen; Eb, ebselen; BW, body weight; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; UACR, urinary albumin to creatinine ratio; NA, not assessed. Data are presented as mean.

doi:10.1371/journal.pone.0069193.t001

Materials and Methods

Ebselen and its Analogues

The Eb analogues, ME and EtE, were synthesized as detailed previously (compounds 18 and 20 respectively, as detailed in Bhabak et al. [23]). Ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one] was purchased from Sapphire Bioscience, NSW, Australia. For in vitro NRK cell-based assays, both Eb and its analogues were made up as a 100 mM stock in DMSO. On the day of treatment, the compounds were further diluted with DMSO to produce a 1.25 mM working solution. To 500 μl of medium in a 6-well culture plate, 1 μl of 1.25 mM Eb or analogue was added, giving a final drug concentration of 2.5 μM. Control wells were treated in the same manner except that 1 μl of DMSO was added instead of drug treatment. For in vitro HAEC cell-based assays, both Eb and its analogues were made up as a 20 mM stock in DMSO. On the day of treatment, the compounds were further diluted with DMSO to produce a 20 μM working solution. To 2 ml of medium in a 6-well culture plate, 1 μl of 20 μM Eb or analogue was added, giving a final drug concentration of 0.01 μM. Control wells were treated in the same manner except that 1 μl of DMSO was added instead of drug treatment.

In vitro Assays in HAEC and NRK Cells

Human Aortic Endothelial cells (HAEC). Cells at passage 4–13 (Cell Application, San Diego, CA, USA) were maintained in endothelial cell media (EGM-2 bullet kit, Lonza, MD, USA) and seeded into 6-well culture plates, pre-coated with 0.2% gelatin. When cultures were 80% confluent, cells were serum deprived for 18 h before experiments were conducted. Cells were pre-treated with 0.01 μM Eb or the analogues for 30 min after which hydrogen peroxide (H$_2$O$_2$; 200 μM, Merck) was added for an additional 30 min in the presence of Eb or the analogues. In separate experiments, control cells were either not treated or treated with 200 μM H$_2$O$_2$ for 30 min; DMSO (vehicle control) or 0.01 μM drug alone for 60 min. In previously published studies, we had determined that treatment with 0.01–0.03 μM Eb was optimal for the inhibition of JNK and IKK activation, whilst significantly inhibiting Nox2 and TNF-α, and without compromising cell viability [26].

Normal Rat Kidney (NRK) cells. Rat kidney tubular epithelial cell line (NRK52E) was obtained from the American Tissue Culture Collection (Rockville, MD, USA) and maintained in Dulbecco’s modified Eagle medium containing 10% serum and 25 mM/l glucose. Cells were starved in 0.1% FBS medium and pre-treated with ME or Eb at 2.5 μM or vehicle (DMSO) for 4 h before being stimulated with TGF-β1 at 10 ng/ml (recombinant human, R&D Systems, Minneapolis, USA) for 72 h. In pilot studies, Eb was used at 0.5, 1.0, 2.5, 5.0, 10 and 20 μM. We determined that 2.5 μM Eb was optimal for the inhibition of TGF-β-stimulated collagen expression, without compromising cell viability (data not shown). Thus, in this study 2.5 μM of Eb and ME was used in all in vitro experiments using NRK cells. Thereafter the cells were collected for either RNA extractions using TRIzol® Reagent (Invitrogen Life Technologies) and analysis by RT-qPCR analysis, or for protein lysates and analysis by Western blots as described previously [25].

Animals

Animal studies were approved by the AMREP Animal Ethics Committee and investigations conformed to National Health and Medical Research Council (NHMRC; Australia) guidelines ( Permit number: E/1034/2010/B). All efforts were made to minimize suffering and diabetic animals had their bedding changed daily to reduce wetness per box. Eight-week old male ApoE/GPx1 dKO mice were rendered diabetic by two intraperitoneal injections of streptozotocin (STZ, Sigma, USA) at 100 mg/kg/day for two consecutive days. Due to the more resistant nature of the β-islet cells of the ApoE/GPx1 mouse to STZ killing, we have previously optimised the dosage of STZ to produce a sustained blood glucose level of around 25 mM for the duration of the study [24,25]. Mice injected with citrate buffer served as non-diabetic controls. At 10-week of age, diabetic and non-diabetic mice were randomised to receive treatment of Eb or ME at 10 mg/kg twice daily by gavage. Since we had previously shown an approximately 50% reduction in plaque in the diabetic ApoE/GPx1 dKO mouse model using this drug regimen [25], we specifically chose this dose for both Eb and ME so that we could compare the results obtained after ME treatment with the expected reductions after Eb treatment. We hypothesized that the more efficacious ME would further reduce the extent of lesions.
compared with the parent compound, Eb. After 12 weeks of treatment, urine was collected for kidney function assessment before the mice were killed by lethal injection of 2,2,2-tribromoethanol (Sigma, USA) and direct puncture of the right ventricle to obtain blood. Aortas and kidney tissue were then collected and fixed in 10% neutral buffered formalin (NBF), whilst the heart sinuses were frozen in OCT after fixation in periodate-lysine-paraformaldehyde (PLP), for subsequent histological analyses. Kidney cortex and medulla were separated and snap frozen in liquid nitrogen for subsequent RNA extraction.

**Evaluation of Atherosclerotic Lesion**

The en face analysis of atherosclerotic lesions was conducted as described previously [24,26], after staining with Sudan IV-Herxheimer’s solution (BDH, Poole, UK), and photographs of opened aortas were digitised using a dissecting microscope (Olympus SZX9; Olympus Optical, Tokyo, Japan) and a digital microscope (Wild Heerbrugg M500; Heerbrugg, Switzerland).

**Figure 3.** Diabetes-associated atherosclerosis is attenuated in the aorta by the ebselen analogue, m-hydroxy ebselen. 14 weeks of diabetes resulted in a significant ~8-fold increase in plaque (stained red) within the aorta of ApoE/GPx1 dKO mice. Treatment with both m-hydroxy ebselen (ME) and ebselen (Eb) at 10 mg/kg twice daily significantly attenuated atherosclerotic plaque deposition within the diabetic aorta. ***P<0.001 vs ND control; ****P<0.001 vs diabetic aorta; NS = not significant. ND = non-diabetic; ME = m-hydroxy ebselen; Diab = diabetic; Eb = ebselen.

**Figure 4.** Diabetes-associated atherosclerosis is attenuated in the aortic sinus region by the ebselen-analogue, m-hydroxy ebselen. Aortic sinus regions of ApoE/GPx1 dKO mice were stained with Oil Red O to detect plaque after 14 weeks of diabetes. Diabetes resulted in a significant ~4-fold increase in plaque within the aorta sinus region. Treatment with both m-hydroxy ebselen (ME) and ebselen (Eb) at 10 mg/kg twice daily significantly attenuated atherosclerotic plaque within the sinus. Although we had previously observed no reduction in aortic sinus lesions after 10 and 20 weeks of ebselen treatment at equivalent concentrations in diabetic ApoE/GPx1 dKO mice [25], we believe that the current study most likely reflects a reduction in the non-lipid components of the plaque by Eb since the entire plaque area was taken into account in the measurement of plaque area in the current study, whilst Oil Red O positive staining for lipid was measured previously. ***P<0.001 vs ND control; **P<0.01 vs diabetic sinus. ND = non diabetic; ME = m-hydroxy ebselen; Diab = diabetic; Eb = ebselen.

---

**Figure 3.** Diabetes-associated atherosclerosis is attenuated in the aorta by the ebselen analogue, m-hydroxy ebselen. 14 weeks of diabetes resulted in a significant ~8-fold increase in plaque (stained red) within the aorta of ApoE/GPx1 dKO mice. Treatment with both m-hydroxy ebselen (ME) and ebselen (Eb) at 10 mg/kg twice daily significantly attenuated atherosclerotic plaque deposition within the diabetic aorta. ***P<0.001 vs ND control; ****P<0.001 vs diabetic aorta; NS = not significant. ND = non-diabetic; ME = m-hydroxy ebselen; Diab = diabetic; Eb = ebselen.

doi:10.1371/journal.pone.0069193.g003

**Figure 4.** Diabetes-associated atherosclerosis is attenuated in the aortic sinus region by the ebselen-analogue, m-hydroxy ebselen. Aortic sinus regions of ApoE/GPx1 dKO mice were stained with Oil Red O to detect plaque after 14 weeks of diabetes. Diabetes resulted in a significant ~4-fold increase in plaque within the aorta sinus region. Treatment with both m-hydroxy ebselen (ME) and ebselen (Eb) at 10 mg/kg twice daily significantly attenuated atherosclerotic plaque within the sinus. Although we had previously observed no reduction in aortic sinus lesions after 10 and 20 weeks of ebselen treatment at equivalent concentrations in diabetic ApoE/GPx1 dKO mice [25], we believe that the current study most likely reflects a reduction in the non-lipid components of the plaque by Eb since the entire plaque area was taken into account in the measurement of plaque area in the current study, whilst Oil Red O positive staining for lipid was measured previously. ***P<0.001 vs ND control; **P<0.01 vs diabetic sinus. ND = non diabetic; ME = m-hydroxy ebselen; Diab = diabetic; Eb = ebselen.

doi:10.1371/journal.pone.0069193.g004
camera (Axiocam colour camera; Carl Zeiss, North Ryde, NSW, Australia). Plaque area was calculated as the proportion of aortic intimal surface area occupied by red stained plaque (Adobe Photoshop v 6.0.1; Adobe Systems, Chatswood, NSW, Australia).

Lesions within the sinus region were visualised after staining of 10 μm sections with Oil Red O staining as described previously [24,26]. The lesional area within the sinus region was quantitated by determining the total plaque area using Image Pro Plus software.

Kidney Function Assessment

Kidney function was assessed by the measurement of urinary albumin to creatinine ratio (ACR). Urinary albumin excretion was measured by a mouse albumin ELISA kit according to manufacturer’s protocols (Bethyl Laboratories, USA). Urinary creatinine was measured by high-performance liquid chromatography (HPLC) method as detailed previously [25]. Albumin to creatinine ratio was then calculated by dividing concentration of albumin (mg/L) to concentration of creatinine (mmol/L) in the urine, and expressed as mg/mmol.

Histological Assessment of Kidney Pathology

For all histological and immunohistochemical staining, six to 12 kidneys were analysed per treatment group (n = 6 to 12 animals per group). For each treatment group, 15–25 glomeruli (at 400× magnification) or at least 10 random non-overlapping fields (at 200× magnification) of the cortex were imaged for quantitation. All image analyses were performed in a blinded manner.

Tubulointerstitial fibrosis. Kidney sections (4 μm) were stained with Masson’s trichrome for the examination of tubulointerstitial matrix accumulation. Tissue sections were pre-fixed in pre-heated Bouin’s solution at 65°C for 30 min. Sections were then covered with Weigert’s iron haematoxylin for 10 min and washed. Slides were placed in 1% Brilliant Crocien (Amber Scientific, WA, Australia) for 15 min for cytoplasmic staining and rinsed in 1% phosphotungstic acid. Sections were then incubated in 0.5% Aniline Blue (ProSciTech, QLD, Australia) in 1% acetic.
Acid to stain for collagen for a further 15 min. Finally, slides were rinsed with 1% acetic acid, dehydrated with 100% ethanol and xylene and coverslipped with DPX (DePeX; Merck, Vic, Australia). All sections were examined under light microscopy (Olympus BX-50; Olympus Optical) and digitised with a high-resolution camera. Proportional areas of matrix (blue staining) were quantitated with imaging software (Image-Pro Plus, v6.0).

Mesangial area. Kidney sections (3 μm) were stained with periodic-acid Schiff (PAS). Mesangial area was analysed from digital images of glomeruli using Image-Pro Plus v6.0 (Media Cybernetics, Bethesda, MD, USA) and expressed as percentage of PAS-stained area per glomerular cross sectional area (gcs).

Glomerulosclerosis. The degree of sclerosis (extent of mesangial matrix accumulation and cellularity) in each glomerulus was subjectively graded on a scale of 0–4 with grade 0 = normal; grade 1 = sclerotic area up to 25% (minimal); grade 2 = sclerotic area 25–50% (moderate); grade 3 = sclerotic area 50–70% (moderate to severe), and grade 4 = sclerotic area 75–100% (severe). The glomerulosclerosis index (GSI) was then calculated using the following formula: 

\[
GSI = \left( \frac{1 \times n_1 + 2 \times n_2 + 3 \times n_3 + 4 \times n_4}{n_0 + n_1 + n_2 + n_3 + n_4} \right)
\]

where \( n_x \) is the number of glomeruli in each grade of glomerulosclerosis.

Immunohistochemistry

Paraffin sections of kidney (4 μm) and frozen aortic sinus sections (10 μm) were used to stain for nitrotyrosine (rabbit polyclonal, Chemicon, MA, USA), which is a marker for peroxynitrite-induced damage in the tissue. The bioactivity of transforming growth factor-β (TGF-β) was assessed by measuring the activation of its downstream mediator, phosphorylated Smad2, using rabbit polyclonal antibody which detect the levels of Smad2/3 only when dually phosphorylated at Ser465 and Ser467 (Cell Signaling, MA, USA). Podocytes were identified using a rabbit monoclonal antibody against Wilms Tumor Protein (WT1; Abcam, MA, USA), which serves as a marker for mature podocyte nuclei [27]. The deposition of collagen IV surrounding the tubulointerstitium was assessed using a goat anti-type IV collagen antibody (Southern Biotech, Birmingham, AL, USA).

Immunohistochemical methods are briefly as follows. After hydration of sections, endogenous peroxidases were inactivated with 3% H₂O₂. Paraffin sections were incubated with protein blocking agent prior to application of the primary antibody. Primary antibody was left on overnight at 4°C. This was followed by incubation with biotinylated secondary antibody for 10 min at room temperature. Sections were then incubated with Vectastain ABC reagent (Vector Laboratories, CA, USA). Peroxidase activity was identified by reaction with 3,3′-diaminobenzidine tetrahydroy-
8-Hydroxy-2-Deoxy Guanosine EIA

8-hydroxy-2-deoxy guanosine (8-OHdG) was measured in urine by a commercially available EIA kit (StressMarq Biosciences Inc, Victoria, BC, Canada). Urine was diluted 1:100 for non-diabetic mice and 1:10 for diabetic mice and the assay was performed as per the manufacturer’s instructions. Urinary 8-OHdG was measured in urine by a commercially available EIA kit (StressMarq Biosciences Inc, Victoria, BC, Canada).
Kidney. ND = non diabetic; ME = m-hydroxy ebselen; Diab = diabetic; reaction (qRT-PCR)

Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)

RNA from mouse kidney cortex and NRK cells was extracted using TRIzolR Reagent according to previously published methods [25]. Contaminating DNA was removed after treatment with DNA-free™ DNase according to the manufacturer’s specifications (Ambion Inc, Austin, USA). DNA-free RNA was reverse transcribed into cDNA using the Superscript First Strand Synthesis System according to the manufacturer’s specifications (Life Technologies BRL, Grand Island, NY). Gene expression was analysed by real-time quantitative RT-PCR using the Taqman system based on real-time detection of accumulated fluorescence (ABI Prism 7700, Perkin-Elmer Inc., Foster City, CA, USA). Fluorescence for each cycle was analyzed quantitatively by an ABI Prism 7700 Sequence Detection System. (Perkin-Elmer, PE Biosystems). Gene expression was normalised relative to the expression of the housekeeping gene 18S ribosomal RNA (18S rRNA Taqman Control Reagent kit; ABI Prism 7700) that was multiplexed together with the gene of interest. Amplifications were performed with the following time course: 94°C for 2 min; 95°C for 10 min, followed by 50 cycles of 94°C for 20s and 60°C for 1 min. The nucleotide sequences of rat collagen I primers and probes were as follows: 6-FAM (probe) CACACGAGAGGC-GCAAGAA; forward primer TGCCGATGTCGTATACAC; and reverse primer TCTTGCAGTGATAGTGATGTTTC. The probes and primers for rat collagen IV were: 6-FAM (probe) ATTTGG-TAAGCTAAGCAAC; forward primer CACTATTAAACCCG-TAATGTGCCCT; and reverse primer GCAACAGAGGCCCAACGAA. For mouse collagen IV probes and primers: 6-FAM (probe) CAGTGCCCTAAGG; forward primer GCGGTA-CACAGTACGAC; and reverse primer GGAATAGGCC-GATCCACAGTG.

**Statistical Analyses**

The data are expressed as mean ± standard error of mean (SEM). Comparison between groups were analysed by performing one-way ANOVA with Newman-Keuls post hoc test. All statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad Software, La Jolla, CA, USA). A P value <0.05 was considered statistically significant.

**Results**

In vitro Assessments

HAEC. Treatment of HAEC with 200 μM H2O2 resulted in significant increases (P<0.001) in the phosphorylation of ERK and P38 compared with controls. Treatment with Eb did not alter the amount of hydrogen peroxide-mediated phosphorylation of Erk or P38 (Figure 2A). ME and EtE significantly reduced the level of hydrogen peroxide-induced phosphorylation of P38 (P<0.001) as well as lowering the phosphorylation of ERK (P<0.001 for ME and P<0.05 for EtE vs H2O2-treated cells; Figure 2B and C).
Importantly, the reduction in ERK phosphorylation was significantly greater \((P<0.01)\) in the presence of ME \((\sim 71\%)\) than that observed after treatment with EtE \((\sim 40\%)\). Similarly, ME caused a greater inhibition of P38 phosphorylation \((\sim 85\%)\) than that caused by EtE \((\sim 73\%)\) although there was no significant difference between the two treatment groups. These data suggested in in vitro experiments at least that Eb had no inhibitory effect on these two important pro-inflammatory mediators, whilst ME showed greater inhibitory potential than EtE.

### Clinical and Metabolic Parameters

At the end of the treatment period, all diabetic groups displayed significant reductions in body weight consistent with our previous results \([24,25]\) and the known effects of diabetes in these mice. Throughout the study, diabetic dKO mice displayed significantly elevated blood glucose levels \(P<0.001\), Table 1) and on termination had significantly increased blood glucose and glycated haemoglobin levels when compared with non-diabetic dKO mice \(P<0.001\), Table 1). Glucose and glycated haemoglobin were not affected by Eb or ME treatment \(P<0.001\). Consistent with our previous study in diabetic dKO mice \([25]\), there were no significant differences in total cholesterol, HDL and LDL levels in all experimental groups. All diabetic groups displayed increased kidney weight to body weight ratios most likely as a consequence of the diabetes-induced reductions in body weight \(P<0.001\). Consistent with our previous study in diabetic dKO mice \([25]\), there were no significant differences in total cholesterol, HDL and LDL levels in all experimental groups. All diabetic groups displayed increased kidney weight to body weight ratios most likely as a consequence of the diabetes-induced reductions in body weight \(P<0.001\).

Diabetes caused an increase in urinary albumin to creatinine \(UACR\) ratio \(P<0.01\), Table 1) in dKO mice. Twelve weeks of ME gavage resulted in a greater reduction in UACR in the diabetic dKO mice than Eb, although this did not reach significance when compared to vehicle-treated diabetic mice \(P<0.01\).
Atherosclerotic Lesions are Attenuated by ME

**En face.** Diabetes induced an approximately 9-fold increase in total plaque formation in the dKO aortas, which was significantly (P<0.001; 45% reduction in plaques) attenuated by ME. Eb also significantly attenuated total aortic plaque deposition by approximately 45% (Figure 3).

**Aortic sinus lesions.** Diabetes significantly increased lesion deposition within the aortic sinus of dKO mice by approximately 3-fold after 14 weeks of diabetes (P<0.001 vs ND mice aortic sinus; Figure 4). This increase was significantly attenuated (~33%; P<0.01 vs Diab group) by treatment with ME. Eb also significantly attenuated lesions by ~26% (P<0.01) compared with that seen in the diabetic group, albeit to a lesser extent than ME, although this difference between treatment groups was not significantly different.

Aortic Oxidative Stress is Attenuated by ME

Diabetes caused a significant increase in the amount of nitrotyrosine immunostaining in the aortic sinus region of ApoE/GPx1 dKO mice (P<0.05). This was significantly attenuated by both ME and Eb treatment although there was no significant difference between the two treatment groups (Figure 5).

Kidney Morphology

**Tubulointerstitial injury.** Masson’s trichrome staining demonstrated an increased tubulointerstitial fibrosis in the diabetic dKO mice kidney when compared to non-diabetic controls (P<0.001, Figure 6). Treatment of Eb and ME in diabetic animals was associated with significant reduction in the accumulation of matrix in the tubulointerstitium (P<0.05, Figure 6). Collagen IV has been shown to contribute to diabetic tubulointerstitial matrix accumulation [28]. In an attempt to further quantitate the changes observed after Masson’s trichrome staining, we evaluated the effects of Eb and ME on the protein and gene expression of this known fibrotic mediator. As expected, we observed that the mRNA and protein expression of collagen IV was significantly increased in the kidney cortex of diabetic dKO mice (P<0.01 and P<0.05, respectively, Figure 6). Importantly, ME significantly attenuated both collagen IV mRNA and protein expression. Interestingly, in this instance, Eb significantly reduced the protein expression of collagen IV but failed to reduce its mRNA expression, suggesting that the mechanism of action by which Eb reduced collagen IV in the kidney may be post-transcriptional.

**Glomerular injury.** The percentage of PAS-positive material, indicative of mesangial expansion, was significantly increased in the diabetic dKO mice (P<0.001, Figure 7). Furthermore, the glomerulosclerosis index (GSI) of the diabetic dKO mice was significantly higher than non-diabetic controls (P<0.01, respectively, Figure 7). Both the mesangial expansion and glomerulosclerosis were attenuated in Eb and ME-treated diabetic dKO mice (Figure 7). Interestingly, the reduction in PAS staining was more significant after treatment with ME (~35%; P<0.001) than with Eb (~15%; P<0.01) compared to non-treated diabetic glomeruli.

Podocyte injury, which manifests as a decrease in the number of podocytes per glomerulus, is reported to be the strongest predictor of the progression of albuminuria [29]. Since glucose-induced ROS have been shown to be a major contributor to podocyte apoptosis and depletion in experimental diabetes leading to diabetic nephropathy [30], we also measured the extent of WT-1 staining (a podocyte-specific nuclei marker) in the glomeruli of all groups in this study. As shown in Figure 8, diabetes caused a significant reduction in podocyte number in the glomeruli of diabetic dKO mice and may have contributed to the significant increase in the
Collagen I and IV Expression is Attenuated by ME in NRK Cells

When NRK52E cells were stimulated with TGF-β for 72 hours, collagen I and IV mRNA levels were significantly increased in agreement with previous data (Figure 11) [32]. Treatment of ME at 2.5 μM significantly attenuated TGF-β-stimulated increase in collagen I and IV gene expression (P<0.01, Figure 11A) compared to DMSO-treated cells. Treatment of NRK52E cells with Eb reduced collagen I and IV gene expression to the same extent as ME. Furthermore, Western blot analysis demonstrated that collagen IV protein expression was increased in TGF-β-treated NRK52E cells, and that both Eb and ME significantly reduced the TGF-β-induced collagen IV protein expression in these cells (P<0.01, Figure 11B). In addition, both ME and Eb reduced collagen I protein levels by approximately 35% after stimulation with TGF-β (P<0.01 and P=0.05 for ME and Eb, respectively; data not shown).

Discussion and Conclusions

It has been postulated by us [23,33] and others [34,35] that synthetic modifications to enhance the nucleophilic attack by thiols on the sulphur atom of the selenenyl sulphide form of Eb, would improve its efficacy to act as a radical scavenging compound. We had previously extensively characterised a diverse range of GPx mimetics using computational, physicochemical and biochemical methods [23,33]. These studies demonstrated that two compounds, ME and EtE, had properties which were consistent with being significantly more effective GPx mimetics than Eb [23]. As reported in this study, it became important to then examine the biological activity of these compounds using cell based and in vivo models of GPx activity, to determine if such differences translate into effective improvements in GPx performance. Indeed, to date, there have been only limited in vitro and in vivo comparison of GPx mimetic compounds [36]. The results of this study have shown several important aspects relating to the testing of modified Eb analogues in cell based and in vivo models.

Firstly, our study has shown that placement of an electron withdrawing 3-hydroxy moiety on the phenyl ring of Eb renders the derivative compound, ME, more efficacious than Eb in lowering two pro-inflammatory signalling mediators in cell based assays. Indeed, where Eb had no effect on the phosphorylation status of the two mediators, P38 and ERK, the derivative compound ME significantly reduced the phosphorylation of P38 and ERK in human aortic endothelial cells. These results suggest that this derivative may be more effective than Eb in lessening the activation of these two pro-inflammatory mediators known to play significant roles in promoting atherogenesis, possibly via its antioxidant function in removing RO/NS [9,11].

Our results also showed that replacing the N-phenyl group of Eb with a N-(2-hydroxyethyl) substituent renders the derivative compound, EtE, more efficacious than Eb in lowering pro-inflammatory signalling in our cell based assays. However, ME was found to be more efficient than EtE, particularly with respect to the attenuation of ERK phosphorylation. Based on our previous in vitro studies showing the superior activity of ME compared with either EtE or Eb to (1) inhibit the peroxynitrite-mediated nitration of L-tyrosine in biochemical assays [20]; (2) reduce hydrogen peroxide and organic peroxide in the presence of glutathione [23] and (3) together with the new data from this study showing its greater effectiveness in limiting two pro-inflammatory mediators in vitro, we selected ME for further testing in our in vivo diabetic ApoE/GPx1 dKO mouse model. We have previously shown that 20 weeks of diabetes significantly enhances pro-inflammatory and pro-atherogenic mediators as well as atherosclerosis [24] and diabetic kidney disease [25] in ApoE/GPx1 dKO mice. Furthermore, our recent study showed that Eb significantly attenuates pro-inflammatory and pro-atherosclerotic mediators as well as diabetes-associated atherosclerosis and diabetic nephropathy after 20 weeks of treatment in the diabetic ApoE/GPx1 dKO mice [25].

In this study, we now confirm and expand on our initial findings by demonstrating that ME, in an analogous fashion to the parent compound Eb, reduces oxidative stress and diabetes-associated atherosclerosis in the diabetic ApoE/GPx1 dKO mouse. Furthermore, ME also lowered diabetes-associated oxidative stress within the interstitial region of the diabetic dKO kidney. Previous studies have shown that ROS are implicated in TGF-β-mediated tubulointerstitial fibrosis and glomerulosclerosis in diabetic nephropathy [37]. Consistent with previous studies [38], we now show a cumulative reduction in oxidative stress, and a reduction in the activity of the pro-fibrotic cytokine, TGF-β, as well as reductions in tubulointerstitial fibrosis and glomerulosclerosis within the diabetic kidney through the use of Eb and its analogue. In addition, ME was also effective in reducing albuminuria, the functional readout of diabetic kidney disease. Moreover, the notion that ROS play an important role in TGF-β signalling was further strengthened in our in vivo experiments using NRK52E cells where the antioxidants, Eb and ME, significantly reduced TGF-β-stimulated collagen expression.

However, this study has demonstrated that there was mostly no additional benefit derived from the modified Eb compound with...
respect to further reductions in either structural or functional readouts for DN or diabetes-associated-atherosclerosis over that noted by the parent compound Eb, despite significant improvements for ME versus that of Eb in biochemical and in vitro (cell based) assays. We did however observe a slight improvement in the extent of albuminuria and a greater reduction in mesangial expansion after ME treatment when compared to Eb, suggesting that for this parameter at least, ME has shown better protection against diabetic mesangial injury than Eb. Interestingly, our study has additionally shown that neither Eb nor ME protected against podocyte loss in diabetic mice, thereby eliminating the podocyte as a potential protective mechanism of ME. Our study therefore highlights the importance of in vivo studies in selecting more efficacious Eb analogues since our data demonstrate that biochemical and in vitro assays may only partly anticipate the in vivo situation.

In conclusion, this study has demonstrated the effectiveness of a modified Eb analogue, ME, in lowering end-points of two often linked diabetic complications. These results are in agreement with our previous study using the parent compound Eb and therefore strengthen the notion that bolstering GPx-like activity may be a useful therapeutic strategy to lessen the burden of complications in diabetic patients. This is particularly relevant since clinical findings have shown that reductions in GPx1 activity have been linked to increased cardiovascular disease, both within a diabetic setting and in association with coronary artery disease [39,40,41].

The development of efficacious GPx1 mimetics is therefore of significant clinical relevance in the quest for developing targeted antioxidant treatments to treat diabetic complications. This study has also highlighted the importance of in vivo testing of modified Eb analogues, since in vitro and cell based assays cannot be relied upon to predict the in vivo effectiveness of the Eb analogues.

Acknowledgements

We thank K. Saheeshkumar for his help in synthesizing the eselen analogues and Aozhi Dai for technical assistance.

Author Contributions

Conceived and designed the experiments: JBH SMT AS. Performed the experiments: SMT DY AS NS. Analyzed the data: SMT DY AS. Contributed reagents/materials/analysis tools: JBH GM ZC. Wrote the paper: JBH SMT GK GM.

References

1. Forsttann U (2008) Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 5: 338–349.
2. Stocker R, Keaney JF, Jr. (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381–1478.
3. Doki T, Cadet J, Ames RN (1996) An adduct between peroxynitrite and 2′-deoxyguanosine: 4,5-dihydro-5- hydroxy-(+/-)nitroso-2′-deoxyguanosine. Chem Res Toxicol 9: 3–7.
4. Moore KP, Darley-Usmar V, Morcos J, Roberts LJ, Zal T (1995) Formation of F2-isoprostanes during the oxidation of human low density lipoprotein by peroxynitrite. Adv Prostaglandin Thromboxane Leukot Res 23: 225–227.
5. Rathnayake C, Souza JM, Duran R, Cassina A, Cervenancs K, et al. (2005) Time course and site(s) of tyrosine c tyrosine nitration by peroxynitrite. Biochemistry 44: 8936–8946.
6. Blanchard-Fillon B, Souza JM, Fried T, Jiang GC, Vrana K, et al. (2001) Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J Biol Chem 276: 46017–46023.
7. Saito Y, Nishih K, Ogawa Y, Kimata J, Kinnumi T, et al. (2006) Turning point in apoptosis/necrosis induced by hydrogen peroxide. Free Radic Res 40: 619–630.
8. Palomina L, Sestili P, Columbaro M, Falcieri E, Cantoni O (1999) Apoptosis and necrosis following exposure of U937 cells to increasing concentrations of hydrogen peroxide: the effect of the poly(ADP-ribose)polymerase inhibitor 3-amino-benzamide. Biochem Pharmacol 58: 1743–1750.
9. Breton-Romero R, Gonzalez de Orduna C, Romero N, Sanchez-Gomez FJ, de Alvaco G, et al. (2012) Critical role of hydrogen peroxide signaling in the sequential activation of p38 MAPK and eNOS in laminar shear stress. Free Radic Biol Med 52: 1093–1110.
10. Wu J, Mei C, Vlassara H, Striker GE, Zheng F (2009) Oxidative stress-induced JNK activation contributes to proinflammatory phenotype of aging diabetic mesangial cells. J Am Physiol Renal Physiol 297: F1622–1631.
11. Werle M, Schmal U, Hanna K, Kreuzer J (2002) MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells. Cardiovasc Res 56: 284–292.
12. Sies H, Sharon VS, Klotz LO, Briviba K (1997) Glutathione peroxidase protects against peroxynitrite-mediated oxidations. A new function for selenoproteins as peroxynitrite reductase. J Biol Chem 272: 27612–27617.
13. May BJ (2000) Catalase and glutathione peroxidase mimics. Biochem Pharmacol 70: 285–296.
14. Jauslin ML, Wirth M, Teier M, Schomacher F (2002) A cellular model for Friedrich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum Mol Genet 11: 3035–3043.
15. Ceriello A (2003) New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care 26: 1589–1596.
16. Baynes JW (1991) Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405–412.
17. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Diabetes Care 25: 2178–2187.
18. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Physiol Rev 84: 1381–1478.
19. Giugliano D, Ceriello A, Paolisso G (1996) Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257–267.
20. Bhabak KP, Vermekar AA, Jodka SR, Roy G, Mugesh G (2011) Mechanistic investigations on the efficient catalytic decomposition of peroxynitrite by eselen analogues. Org Biomol Chem 9: 5193–5200.
21. Masumoto H, Kimura R, Koppelnok WH, Sies H (1996) Kinetic study of the reaction of eselen with peroxynitrite. FEBS Lett 398: 179–182.
22. Sarma BR, Mugesh G (2003) Glutathione peroxidase GPx-like antioxidant activity of the organoselenium drug eselen: unexpected complications with thiol exchange reactions. J Am Chem Soc 127: 11477–11485.
23. Bhabak KP, Mugesh G (2007) Synthesis, characterization, and antioxidant activity of some eselen analogues. Chem 15: 4504–4505.
24. Levie P, Stefanovic N, Pet J, Calkin AC, Giunti S, et al. (2007) Lack of the Antioxidant Enzyme Glutathione Peroxidase-1Accelerates Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice. Circulation 115: 2178–2187.
25. Chew P, Yuen DYC, Stefanovic N, Pet J, Coughlan MT, et al. (2010) Antiatherosclerotic and proreparative effects of eselen in the diabetic ebselen (GPx1) double knockout mouse. Diabetes 59: 3198–3207.
26. Chew P, Yuen DYC, Koh P, Stefanovic N, Febbraio MA, et al. (2009) Site-Specific Antithrombosis Effect of the Antioxidant Eselen in the Diabetic Apolipoprotein E-Deficient Mouse. Arteriosclerosis, Thrombosis, and Vascular Biology 29: 823–830.
27. Sanden SK, Wiggins JE, Goyal M, Rigs J, Wiggins RC (2003) Evaluation of a Thick and Thin Section Method for Estimation of Podocyte Number, Glomerular Volume, and Glomerular Volume Per Podocyte in Rat Kidney with Wilms’ Tumor-1 Protein Used as a Podocyte Nuclear Marker. Journal of the American Society of Nephrology 14: 2494–2493.
28. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen UL, et al. (1998) Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 47: 414–422.
29. Meyer TW, Bennett PH, Nelson RG (1999) Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 42: 1341–1344.
30. Szutz K, Raff AC, Schiller M, Bottiger EP (2006) Glucose-Induced Reactive Oxygen Species Cause Apoptosis of Podocytes and Podocyte Depletion at the Onset of Diabetic Nephropathy. Diabetes 55: 225–233.
31. Blauwvamp M, Yu J, Shin M, Burke K, Berry M, et al. (2000) Podocyte specific knock out of selenoproteins does not enhance nephropathy in streptozotocin diabetic C57BL/6 mice. BMC Nephrology 9: 7.
32. Wang B, Konmers R, Carew R, Wiinbanks CE, Xu B, et al. (2012) Suppression of microRNA-29 Expression by TGF-b1 Promotes Collagen Expression and Renal Fibrosis. Journal of the American Society of Nephrology 23: 2522–2523.
33. Bhabak KP, Mugesh G (2008) A simple and efficient strategy to enhance the antioxidant activities of amino-substituted glutathione peroxidase mimics. Journal of the American Society of Nephrology 23: 414–422.
34. Galet V, Bernier JL, Henchart JP, Lesieur D, Abadie C, et al. (1994) Peroxynitrite reductase. J Biol Chem 269: 405–412.
36. Hort MA, Straliotto MR, Netto PM, da Rocha JB, de Bem AF, et al. (2011) Diphenyl diselenide effectively reduces atherosclerotic lesions in LDLr−/−mice by attenuation of oxidative stress and inflammation. J Cardiovasc Pharmacol 58: 91-101.

37. Lee HB, Yu M-R, Yang Y, Jiang Z, Ha H (2003) Reactive Oxygen Species-Regulated Signaling Pathways in Diabetic Nephropathy. J Am Soc Nephrol 14: S241–245.

38. Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, et al. (2005) Role of reactive oxygen species in TGF-β1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. Journal of the American Society of Nephrology 16: 667–675.

39. Blankenberg S, Rupprecht HJ, Bickel G, Torzewski M, Hafner G, et al. (2003) Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 349: 1605–1613.

40. Hamanishi T, Furuta H, Kato H, Doi A, Tamai M, et al. (2004) Functional variants in the glutathione peroxidase-1 (GPx1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in Japanese type 2 diabetic patients. Diabetes 53: 2455–2460.

41. Winter JP, Gong Y, Grant PJ, Wild CP (2003) Glutathione peroxidase 1 genotype is associated with an increased risk of coronary artery disease. Coron Artery Dis 14: 149–153.